ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
Avatar

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to BCMA-Directed Therapy

By ASH 2022 Conference Coverage FEATURING Shebli Atrash
By ASH 2022 Conference Coverage FEATURING Shebli Atrash
136 views
December 19, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey
Myeloma
07:05

ASH 2022 Phase 1/2 Results From MonumenTAL-1: Talquetamab, a G Prote…

ASH 2022 Conference Coverage

A. Chari

206 views
07:25

ASH 2022 Results of the ASCENT Trial: Fixed Duration Therapy With Da…

ASH 2022 Conference Coverage

S. Kumar

79 views
10:37

ASH 2022 Mezigdomide (CC-92480) + Dex in R/R MM: Preliminary Results…

ASH 2022 Conference Coverage

P. Richardson

178 views
24:01

ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next B…

ASH 2022 Conference Coverage

Y. Efebera

225 views
07:37

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethasone in…

ASH 2022 Conference Coverage

T. Martin

1.5K views
10:37

ASH 2022 Subsequent Antimyeloma Therapies From ICARIA-MM Study: Pom/…

ASH 2022 Conference Coverage

P. Richardson

109 views
06:25

ASH 2022 Phase 3 EMagine/CARTITUDE-6 Trial: DVRd Followed by either …

ASH 2022 Conference Coverage

P. Sonneveld

122 views
11:25

ASH 2022 MAIA Trial Age Subgroup Analysis: Daratumumab + Lenalidomid…

ASH 2022 Conference Coverage

T. Plesner

81 views
15:03

ASH 2022: A Consultant’s Guide to Smoldering Multiple Myeloma

ASH 2022 Conference Coverage

S. Thorsteinsdottir

135 views
04:10

ASH 2022 SubQ Isatuximab + Carfilzomib & Dexamethasone in Relapsed M…

ASH 2022 Conference Coverage

H. Quach

170 views
20:46

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -B…

ASH 2022 Conference Coverage

F. Pichiorri

203 views
11:12

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic…

ASH 2022 Conference Coverage

J. Miller

80 views
05:18

ASH 2022 Phase II DEDALO Trial: Daratumumab + Pomalidomide & Dexamet…

ASH 2022 Conference Coverage

V. Montefusco

43 views
14:16

Assessing Disease Risk in Multiple Myeloma: High or Low?

ASH 2022 Conference Coverage

T. Schmidt

142 views
03:00

ASH 2022 Phase 1 MagnetisMM-1 Trial: Elranatamab, a BCMA Targeted T-…

ASH 2022 Conference Coverage

N. S. Raje

64 views
06:16

U.S. Myeloma CAR-T Consortium Real World Experience: Factors Associa…

ASH 2022 Conference Coverage

H. Hashmi

217 views
08:24

ASH 2022 Once Weekly Selinexor, Carfilzomib & Dexamethasone (XKd) in…

ASH 2022 Conference Coverage

G. Schiller

52 views
10:08

ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM…

ASH 2022 Conference Coverage

N. Korde

413 views
10:34

ASH 2022 Phase 1/2 LINKER-MM1 Study of Linvoseltamab, a BCMAxCD3 Bis…

ASH 2022 Conference Coverage

N. Bumma

91 views
07:17

ASH 2022 Phase 3 VITAL Study: Survival Benefit of Birtamimab in Mayo…

ASH 2022 Conference Coverage

M. Gertz

78 views
05:05

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to…

ASH 2022 Conference Coverage

S. Atrash

136 views
15:32

Novel Approaches to Myeloma Burden Assessment

ASH 2022 Conference Coverage

T. Kourelis

261 views
14:03

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

ASH 2022 Conference Coverage

S. Parekh

74 views
05:56

ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…

ASH 2022 Conference Coverage

G. Morgan

906 views
14:23

ASH 2022 Phase I Dose-Escalation Study of Forimtamig (RG6234), a GPR…

ASH 2022 Conference Coverage

C. Carlo-Stella

55 views
04:31

ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …

ASH 2022 Conference Coverage

A. Chari

768 views